As efficient and effective tools for gene transduction and delivering genes to target cell populations, viral vectors are helping drive the increasing popularity of cell and gene therapies (C>s). Commonly used viral vectors include adeno-associated virus (AAV), gamma retrovirus, and lentiviruses.
In C>s, lentiviruses are increasingly becoming the vector of choice for Chimeric Antigen Receptor T cell (CAR -T) therapies, offering high viral titers, as well as the ability to carry a large cassette and integrate the gene of interest into the host cell’s genome.
However, undertaking a lentiviral development and manufacturing project requires many factors to be considered at every stage of production. From plasmid design and pseudotyping to choosing between adherent and suspension cultures at upstream development, optimizing downstream purification methods, and performing the necessary analytical tests, each decision is critical.
With extensive expertise in lentiviral development and manufacturing, Genezen understands the importance of making the right choices throughout the lentivirus production process, helping to ensure the success of your project at all stages .
For insight into whether lentiviral vectors could be best suited for your next gene therapy project and the potential challenges that must be overcome to ensure success, download our lentiviral development and manufacturing whitepaper by completing the form to the right.
